Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIDEX: Dexmedetomidine vs Midazolam for ICU Sedation
NCT00481312Phase 3Completed
- Sponsor
- Orion Corporation
- Start
- Jun 2007
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of dexmedetomidine in sedation (2 arms), sponsored by Orion Corporation. Primary endpoints: Depth of sedation using the RASS up to 14 days and Duration of mechanical ventilation up to 45 days. Started Jun 2007; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
sedation
Beyond the preview
Go deeper on NCT00481312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00481312.